Immunocore(IMCR) - 2025 Q4 - Earnings Call Transcript

Financial Data and Key Metrics Changes - For the year 2025, the company generated $400 million in net revenue from KIMMTRAK, representing a 29% increase from the prior year [4][7][24] - The operating loss was reduced in 2025 as revenue growth outpaced operating expenses [26] - The balance sheet remains strong with approximately $864 million in cash and marketable securities, an increase of over $40 million from the previous year [26] Business Line Data and Key Metrics Changes - KIMMTRAK is now approved in 39 countries and launched in 30 markets, with over 70% penetration across all major markets [4][7] - The mean duration of therapy for KIMMTRAK is 14 months, exceeding clinical trial experiences [4][7] - The company activated 150 new accounts in 2025, with 70% of all KIMMTRAK prescriptions coming from community settings [9] Market Data and Key Metrics Changes - KIMMTRAK's adoption is widespread, with half of all patient starts occurring in community settings [9] - The company expects moderating growth in 2026, with underlying sequential quarterly revenue growth in the range of 4%-7% [24] Company Strategy and Development Direction - The company is expanding the reach of KIMMTRAK through a lifecycle management program with two phase III trials: TEBE-AM and ATOM [5][6] - The oncology platform is being expanded beyond melanoma into ovarian and lung colorectal cancers [6][17] - The company aims to achieve tissue-specific down modulation of the immune system in autoimmune diseases, with a focus on type 1 diabetes and atopic dermatitis [20] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the growth trajectory of KIMMTRAK and the potential to serve a larger patient population [10][11] - The company anticipates that 2026 will be a year of data and continued progress, with significant investments in R&D [27] Other Important Information - The company has three ongoing phase III trials in oncology, with data readouts expected beginning in the second half of 2026 [12][18] - The company presented promising data for its HIV functional cure program and hepatitis B candidate, confirming the potential of its platform in infectious diseases [6][19] Q&A Session Summary Question: Geographic breakdown of TEBE-AM enrollment - The majority of enrollment is coming from Europe, with 10%-15% from the U.S. [30] Question: Statistical assumptions for TEBE-AM treatment arms - The study is designed to meet statistically significant and clinically meaningful thresholds, typically at least a 30% difference from the control [35] Question: Expectations for revenue growth in 2026 - The company expects growth to moderate, with underlying growth around 20% when normalizing for rebate reserves [39] Question: Pricing strategy for potential cutaneous melanoma indication - The company believes it can defend its pricing based on the unmet need and established safety profile if data is positive [45] Question: Evaluation of success in early autoimmune studies - The company will assess binding to the target and measure surrogate markers like C-peptide for efficacy [50] Question: Insights from KIMMTRAK's success in uveal melanoma for cutaneous melanoma - Half of the cutaneous melanoma patients are treated by physicians experienced with KIMMTRAK, providing a strong foundation for a potential launch [54]